Aquestive Therapeutics Sued in Class Action Over Investor Losses

Edgen Stock

·Mar 11 2026, 14:57

Share to

Share to

Copy link

Key Takeaways

A class-action lawsuit has been filed against Aquestive Therapeutics, Inc. by the law firm Johnson Fistel, alleging violations of federal securities laws. The legal action, announced on March 11, 2026, introduces significant financial and reputational risk for the company and its investors, covering a specific period of stock purchases.

Lawsuit Filed: A class-action lawsuit targets Aquestive Therapeutics (AQST) on behalf of investors who purchased its securities.
Defined Class Period: The suit covers all securities acquired between June 16, 2025, and January 8, 2026, inclusive.
Investor Risk: The legal proceedings create potential for increased stock volatility and significant financial liabilities for the company, posing a risk to shareholder value.

Lawsuit Alleges Losses for Investors from June 2025 to January 2026

On March 11, 2026, law firm Johnson Fistel, PLLP announced the filing of a class-action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST). The suit was filed on behalf of investors who purchased or otherwise acquired the company's securities between June 16, 2025, and January 8, 2026. The legal action seeks to recover damages for Aquestive investors under federal securities laws.

Legal Action Exposes AQST to Financial and Reputational Risk

The initiation of this lawsuit introduces considerable uncertainty for Aquestive Therapeutics and its shareholders. The company now faces the prospect of substantial legal costs and potential financial liabilities from a settlement or adverse judgment. Furthermore, such litigation can damage a company's reputation, potentially eroding investor confidence and creating selling pressure on its stock. Investors will be closely watching for any company response and developments in the legal proceedings.